Drugs.com - Clinical Trials

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

HIGH POINT, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being...

Mar 18, 2025 - 00:15
 0
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
HIGH POINT, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being...
Read More

Tags:

Previous Article

France : Un marché de la beauté atone tiré par les ventes en pharmacies

Next Article

BioArctic Receives Orphan Drug Designation for Exidavnemab the US

Related Posts

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advan...

Mar 5, 2025  0

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Vaxart Announces Clinical Trial Initiation of Norovirus...

Mar 12, 2025  0

Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies

Phase III Study Shows Xolair May Be More Effective With...

Mar 4, 2025  0